| scholarly article | Q13442814 |
| P2093 | author name string | Richard S E Keefe | |
| James Wu | |||
| Manisha Madhoo | |||
| Madhukar H Trivedi | |||
| Robert M Roth | |||
| Angelo Sambunaris | |||
| Robert Lasser | |||
| Colleen S Anderson | |||
| P2860 | cites work | Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis | Q21143851 |
| The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R) | Q29547223 | ||
| Identifying neurocognitive impairment in depression using computerized testing | Q83027736 | ||
| A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity | Q29547290 | ||
| A New Depression Scale Designed to be Sensitive to Change | Q29614720 | ||
| Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report | Q29615999 | ||
| Reliability and construct validity of the Changes in Sexual Functioning Questionnaire short-form (CSFQ-14). | Q30438433 | ||
| Executive functions and their disorders | Q30786154 | ||
| Identifying a cognitive impairment subgroup in adults with mood disorders | Q33775582 | ||
| Subjective rating of working memory is associated with frontal lobe volume in schizophrenia | Q33976468 | ||
| Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design | Q34011677 | ||
| Placebo response in studies of major depression: variable, substantial, and growing | Q34122652 | ||
| Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions | Q34425639 | ||
| Cognitive disturbance in outpatient depressed younger adults: evidence of modest impairment | Q34469071 | ||
| A brief measure for assessing generalized anxiety disorder: the GAD-7. | Q34529333 | ||
| The pharmacological management of depression | Q35236630 | ||
| Executive and prefrontal dysfunction in unipolar depression: a review of neuropsychological and imaging evidence | Q35853198 | ||
| Executive dysfunction in major depressive disorder | Q36106773 | ||
| Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review | Q36218444 | ||
| Stimulants: Therapeutic actions in ADHD. | Q36541590 | ||
| Sheehan Suicidality Tracking Scale (Sheehan-STS): Preliminary Results from a Multicenter Clinical Trial in Generalized Anxiety Disorder | Q37285367 | ||
| Cognitive impairment in major depression | Q37616311 | ||
| Contribution of rating scales to the assessment of executive functions | Q38084730 | ||
| Neurocognition in depression: patients on and off medication versus healthy comparison subjects | Q38406779 | ||
| A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram | Q38444868 | ||
| Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder. | Q43102560 | ||
| Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients | Q44255099 | ||
| Sex differences in cognitive estimation during sleep deprivation: effects of stimulant countermeasures | Q46318073 | ||
| Health related quality of life in recurrent depression: a comparison with a general population sample | Q46348839 | ||
| Cognitive and behavioral effects of multilayer-release methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder | Q46738479 | ||
| A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder | Q46799870 | ||
| Academic procrastination in college students: The role of self-reported executive function | Q48169346 | ||
| Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder. | Q48374137 | ||
| Reliability and validity of a computerized neurocognitive test battery, CNS Vital Signs | Q48407201 | ||
| Self- and informant reports of executive function on the BRIEF-A in MCI and older adults with cognitive complaints | Q48419500 | ||
| Computerized neuropsychological testing to rapidly evaluate cognition in pediatric patients with neurologic disorders. | Q50970456 | ||
| Cognitive deficits in the euthymic phase of unipolar depression. | Q51890300 | ||
| Psychometric evaluation of the Amphetamine Cessation Symptom Assessment. | Q51901566 | ||
| Cognitive impairment in unipolar depression is persistent and non-specific: further evidence for the final common pathway disorder hypothesis. | Q51962925 | ||
| Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. | Q51984407 | ||
| Efficacy of Duloxetine on Cognition, Depression, and Pain in Elderly Patients With Major Depressive Disorder: An 8-Week, Double-Blind, Placebo-Controlled Trial | Q56780593 | ||
| Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure | Q72729639 | ||
| Endicott Work Productivity Scale (EWPS): a new measure to assess treatment effects | Q73303392 | ||
| A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder | Q79733638 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | executive disfunction | Q5419936 |
| major depressive disorder | Q42844 | ||
| P304 | page(s) | 1388-1398 | |
| P577 | publication date | 2013-12-06 | |
| P1433 | published in | Neuropsychopharmacology | Q2261280 |
| P1476 | title | Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder | |
| P478 | volume | 39 |
| Q89136877 | A 12-Month Open-Label Extension Study of the Safety and Tolerability of Lisdexamfetamine Dimesylate for Major Depressive Disorder in Adults |
| Q91599142 | A Review of Psychostimulants for Adults With Depression |
| Q42361284 | A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy |
| Q55334438 | Addictive potential of novel treatments for refractory depression and anxiety. |
| Q41495299 | Adult ADHD and comorbid disorders: clinical implications of a dimensional approach |
| Q94452523 | Altered GABA-mediated information processing and cognitive dysfunctions in depression and other brain disorders |
| Q48052666 | Association of psychological, cognitive, and functional variables with self-reported executive functioning in a sample of nondemented community-dwelling older adults |
| Q37197216 | Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments |
| Q92897506 | Cognitive Dysfunction in Major Depressive Disorder: Assessment, Impact, and Management |
| Q35006371 | Cognitive dysfunction in major depressive disorder: effects on psychosocial functioning and implications for treatment |
| Q93365995 | Cognitive impairment in major depressive disorder |
| Q26775386 | Cognitive remission: a novel objective for the treatment of major depression? |
| Q38797653 | Drugs, games, and devices for enhancing cognition: implications for work and society |
| Q36880463 | Effect of antidepressant treatment on cognitive impairments associated with depression: a randomised longitudinal study |
| Q95642618 | Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers |
| Q38859885 | Managing comorbid obesity and depression through clinical pharmacotherapies |
| Q28076105 | Neurobiology of hedonic tone: the relationship between treatment-resistant depression, attention-deficit hyperactivity disorder, and substance abuse |
| Q26752974 | Novel pharmacologic treatment in acute binge eating disorder - role of lisdexamfetamine |
| Q38300369 | Pharmacological approaches to manage persistent symptoms of major depressive disorder: rationale and therapeutic strategies |
| Q34515266 | Stimulants for depression: On the up and up? |
| Q38569937 | The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder |
| Q38221823 | The use of lisdexamfetamine dimesylate for the treatment of ADHD and other psychiatric disorders. |
| Q48060609 | Treating cognitive impairment in depression: an unmet need |
| Q38673546 | Treating to target in major depressive disorder: response to remission to functional recovery |
Search more.